卡维地洛对心绞痛患者同型半胱氨酸、内皮素及血管性假血友病因子的影响

Effects of carvedilol on homocysteine,endothelin and von willebrand factor in patients with unstable angina pectoris

目的 观察卡维地洛对不稳定型心绞痛 (unstableanginapectoris,UAP)患者同型半胱氨酸(homocysteine ,Hcy)、内皮素 (endothelin ,ET)及血管性假血友病因子 (vonwillebrandfactor,vWF)的影响。方法 健康对照组 2 0例未予干预。 4 0例UAP患者随机分成苯那普利组 (10mg/d ,× 3d ,n=2 1)和卡维地洛组 (4 0mg/d ,× 3d ,n =19)。采用放射免疫法和ELISA法测定Hcy、ET及vWF值。结果 (1)用药前UAP患者的Hcy、ET和vWF显著高于健康对照组 (P <0 0 5 ) ;(2 )卡维地洛组患者用药后Hcy、ET及vWF显著下降 (P <0 0 5 ) ;(3)苯那普利组患者用药后Hcy、ET及vWF无显著改变 (P值均大于 0 0 5 )。结论 卡维地洛可显著降低不稳定型心绞痛患者的Hcy。

Objective To investigate effects of carvedilol on the levels of homocysteine(Hcy), endothelin(ET) and von willebrand factor(vWF) in patients with unstable angina pectoris. Methods Forty patients with unstable angina pectoris (UAP) were randomly divided into two groups: benazeptil group (10 mg/day,×3d, n=21) and carvedilol group (40 mg/day,×3d, n=19).Twenty healthy volunteers served as control group. The levels of ET, Hcy and vWF were measured with radioimmunoassay (RIA) or enzyme linked immunosobent assay (ELISA).Results Compared with control group,levels of Hcy, ET and vWF in patients with UAP increased significantly (P<0.05). The concentrations of Hcy, ET and vWF in carvedilol group decreased markedly (P<0.05), while those in benazeptil group did not change (P>0.05). Conclusion Carvedilol can decrease levels of Hcy, ET and vWF in patients with UAP.